Table 6 Predictors of culture conversion at 6 months in the patients with MDR/RR/pre-XDR-TBTB.

From: Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Characteristic

Unadjusted OR (95% CI)

P value

Adjusted OR (95% CI)

P value

Age

1.028(0.982, 1.075)

0.241

  

BMI < 18.5 kg/m2

0.622 (0.233, 1.657)

0.342

  

Male

1.733 (0.666, 4.514)

0.260

  

Ever smoker

0.955 (0.315, 2.894)

0.934

  

Diabetes mellitus

1.225(0.222, 6.764)

0.816

  

TB treatment history

2.300 (0.803, 6.589)

0.121

0.640

Positive AFB smear at treatment initiation

0.553 (0.217, 1.410)

0.215

  

Imagining features

    

 Lung damage

1.739 (0.437, 6.922)

0.432

  

 Pulmonary atelectasis

0.694 (0.273, 1.770)

0.445

  

 Cavity

1.339 (0.520, 3.449)

0.546

  

 Bilateral disease

0.413 (0.107, 1.597)

0.200

  

Subtypes of TBTB

    

 Inflammatory infiltration

2.724 (0.820, 9.050)

0.102

0.086

 Ulceration necrosis

0.545 (0.211, 1.408)

0.210

  

 Granulation hyperplasia

0.958 (0.261, 3.513)

0.949

  

 Cicatrices stricture

0.864 (0.299, 2.496)

0.787

  

Multiple bronchi involved under bronchoscopy

0.537 (0.206, 1.398)

0.203

  

Tracheobronchial stenosis under bronchoscopy

0.243 (0.065, 0.913)

0.036

0.144

Tracheobronchial obstructionunder bronchoscopy

1.250 (0.354, 4.420)

0.729

  

Treatment

    

 Treatment with bedaquiline

8.000 (2.160, 29.636)

0.002

13.333 (3.379, 52.610)

< 0.001

 Treatment with delamanid

1.917 (0.565, 6.505)

0.297

5.000 (1.357, 18.426)

0.016

 Treatment with any FQ

0.367 (0.110, 1.220)

0.102

0.682

 Treatment with linezolid

1.283 (0.440, 3.747)

0.648

0.148

 Treatment with SLID

0.467 (0.170, 1.282)

0.139

0.245

 Interventional therapy

1.143(0.271, 4.814)

0.856

0.878

 Surgical resection

0.463 (0.062, 3.478)

0.454

0.703

  1. AFB acid-fast bacilli, BMI body mass index, CI confidence interval, DST drug susceptibility testing, FQ fluoroquinolone, HIV human immunodeficiency virus, OR odds ratio, SLID second-line injectable drug.